GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Other Income (Expense)

ADC Therapeutics (ADC Therapeutics) Other Income (Expense) : $5.42 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Other Income (Expense)?

ADC Therapeutics's other income expense for the ADC Therapeutics's pretax income for the three months ended in Dec. 2023 was $7.26 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was $5.42 Mil.

ADC Therapeutics Other Income (Expense) Historical Data

The historical data trend for ADC Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Other Income (Expense) Chart

ADC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial -0.25 -23.19 28.12 10.33 5.42

ADC Therapeutics Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.38 -0.14 -0.77 -0.93 7.26

ADC Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADC Therapeutics  (NYSE:ADCT) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Other Income (Expense)
Comparable Companies
IOBT TSBX ACET HCWB ANEB XLO CLGN ATHA KZR ELTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
Website
https://www.adctherapeutics.com
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.